Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 126 results for epilepsies

  1. Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. 24/7 EEG SubQ for epilepsy (MIB277)

    NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .

    Medtech innovation briefing
    Published
    2 November 2021

  3. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (HTG541)

    Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a laser into the area of the brain causing seizures.

    HealthTech guidance
    Published
    4 March 2020
    View recommendations

    Sections for HTG541

  4. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development

  5. Vagus nerve stimulation for refractory epilepsy in children (HTG25)

    Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.

    HealthTech guidance
    Published
    24 March 2004
    View recommendations

    Sections for HTG25

  6. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

    NICE guideline
    Last updated
    2 October 2023

    Sections for NG127

  7. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  8. Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes with onset in childhood, for example, myoclonic-astatic epilepsy and Dravet syndrome?

    CG137/2 Question Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy...

    Research recommendation
    Published
    13 August 2021

  9. Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death.

    all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death...

    Research recommendation
    Published
    11 May 2022

  10. Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated?

    Question Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex...

    Research recommendation
    Published
    11 May 2022

  11. Psychological treatments: What is the cost effectiveness of providing tailored psychological treatments for people with epilepsy?

    effectiveness of providing tailored psychological treatments for people with epilepsy? Any explanatory notes(if applicable) For a short...

    Research recommendation
    Published
    11 May 2022

  12. Antibody testing: What immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes?

    immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes? Any explanatory notes(if applicable) For...

    Research recommendation
    Published
    11 May 2022

  13. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG62

  14. Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy?

    clinical and cost effectiveness of digital health technologies in people with epilepsy? Any explanatory notes(if applicable) For a short...

    Research recommendation
    Published
    11 May 2022

  15. Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)?

    stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a...

    Research recommendation
    Published
    11 May 2022